NO20090783L - Pyrimidonforbindelser som inhibitorer av GSK-3 - Google Patents
Pyrimidonforbindelser som inhibitorer av GSK-3Info
- Publication number
- NO20090783L NO20090783L NO20090783A NO20090783A NO20090783L NO 20090783 L NO20090783 L NO 20090783L NO 20090783 A NO20090783 A NO 20090783A NO 20090783 A NO20090783 A NO 20090783A NO 20090783 L NO20090783 L NO 20090783L
- Authority
- NO
- Norway
- Prior art keywords
- gsk
- inhibitors
- pyrimidone compounds
- pyrimidone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Det beskrives pyrimidon-derivater (I) som har aktivitet som GSK-3-inhibitorer. Oppfinnelsen vedrører videre farmasøytiske sammensetninger omfattende slike derivater og anvendelser derav for behandling av visse forstyrrelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82326706P | 2006-08-23 | 2006-08-23 | |
PCT/IB2007/002390 WO2008023239A1 (en) | 2006-08-23 | 2007-08-13 | Pyrimidone compounds as gsk-3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090783L true NO20090783L (no) | 2009-03-13 |
Family
ID=38670755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090783A NO20090783L (no) | 2006-08-23 | 2009-02-18 | Pyrimidonforbindelser som inhibitorer av GSK-3 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100292205A1 (no) |
EP (1) | EP2057141B1 (no) |
JP (1) | JP2010501540A (no) |
KR (1) | KR20090052884A (no) |
CN (1) | CN101528729A (no) |
AT (1) | ATE530540T1 (no) |
AU (1) | AU2007287319A1 (no) |
CA (1) | CA2661334C (no) |
ES (1) | ES2373587T3 (no) |
IL (1) | IL197080A0 (no) |
MX (1) | MX2009001913A (no) |
NO (1) | NO20090783L (no) |
WO (1) | WO2008023239A1 (no) |
ZA (1) | ZA200901037B (no) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US8026240B2 (en) | 2007-09-11 | 2011-09-27 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides |
EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
EP2464639A1 (en) * | 2009-08-13 | 2012-06-20 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
MY164789A (en) | 2010-09-13 | 2018-01-30 | Otsuka Pharma Co Ltd | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine |
ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
US8697715B2 (en) | 2012-03-01 | 2014-04-15 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
TW201408658A (zh) | 2012-08-27 | 2014-03-01 | Array Biopharma Inc | 絲胺酸/酥胺酸激酶抑制劑 |
ES2786925T3 (es) | 2013-03-14 | 2020-10-14 | Brigham & Womens Hospital Inc | Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales |
US10568883B2 (en) | 2014-09-03 | 2020-02-25 | Massachusetts Institute Of Technology | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
EP3283486B1 (en) | 2015-04-15 | 2022-07-27 | BeiGene, Ltd. | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
EP3544980B1 (en) * | 2016-11-28 | 2021-10-13 | Bristol-Myers Squibb Company | Gsk-3 inhibitors |
JP7109446B2 (ja) | 2016-12-30 | 2022-07-29 | フリークエンシー セラピューティクス インコーポレイテッド | 幹細胞/前駆支持細胞の自己複製を誘導するための1h-ピロール-2,5-ジオン化合物およびその使用方法 |
BR112020007589A8 (pt) | 2017-10-19 | 2022-08-02 | Amgen Inc | Derivados de benzimidazol e seus usos |
JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法 |
WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びwnt作動薬 |
CN113666878A (zh) * | 2021-08-27 | 2021-11-19 | 宁夏常晟药业有限公司 | 一种5-溴-2-氯嘧啶-4-羧酸甲酯的合成方法 |
WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1136491A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[(Heteroaryl)alkylamino]pyrimidone derivatives |
EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
EP1136489A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperidin-1-yl]pyrimidone derivatives |
EP1136493A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives |
EP1136483A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
WO2001070727A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
EA007576B1 (ru) * | 2001-09-21 | 2006-12-29 | Мицубиси Фарма Корпорейшн | Производные 3-замещенных 4-пиримидонов |
WO2003027080A1 (en) * | 2001-09-21 | 2003-04-03 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
WO2004055007A1 (en) * | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
AU2005288045B2 (en) * | 2004-09-29 | 2011-08-18 | Mitsubishi Tanabe Pharma Corporation | 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
-
2007
- 2007-08-13 MX MX2009001913A patent/MX2009001913A/es not_active Application Discontinuation
- 2007-08-13 KR KR1020097005783A patent/KR20090052884A/ko not_active Application Discontinuation
- 2007-08-13 CN CNA2007800394073A patent/CN101528729A/zh active Pending
- 2007-08-13 CA CA2661334A patent/CA2661334C/en not_active Expired - Fee Related
- 2007-08-13 EP EP07789659A patent/EP2057141B1/en not_active Not-in-force
- 2007-08-13 AT AT07789659T patent/ATE530540T1/de not_active IP Right Cessation
- 2007-08-13 US US12/438,198 patent/US20100292205A1/en not_active Abandoned
- 2007-08-13 JP JP2009525121A patent/JP2010501540A/ja not_active Withdrawn
- 2007-08-13 WO PCT/IB2007/002390 patent/WO2008023239A1/en active Application Filing
- 2007-08-13 ES ES07789659T patent/ES2373587T3/es active Active
- 2007-08-13 AU AU2007287319A patent/AU2007287319A1/en not_active Abandoned
-
2009
- 2009-02-13 ZA ZA200901037A patent/ZA200901037B/xx unknown
- 2009-02-17 IL IL197080A patent/IL197080A0/en unknown
- 2009-02-18 NO NO20090783A patent/NO20090783L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL197080A0 (en) | 2009-11-18 |
ES2373587T3 (es) | 2012-02-06 |
WO2008023239A1 (en) | 2008-02-28 |
CA2661334C (en) | 2011-11-29 |
ATE530540T1 (de) | 2011-11-15 |
EP2057141A1 (en) | 2009-05-13 |
CA2661334A1 (en) | 2008-02-28 |
EP2057141B1 (en) | 2011-10-26 |
AU2007287319A1 (en) | 2008-02-28 |
ZA200901037B (en) | 2010-04-28 |
CN101528729A (zh) | 2009-09-09 |
JP2010501540A (ja) | 2010-01-21 |
MX2009001913A (es) | 2009-03-06 |
US20100292205A1 (en) | 2010-11-18 |
KR20090052884A (ko) | 2009-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090783L (no) | Pyrimidonforbindelser som inhibitorer av GSK-3 | |
NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
NO20090596L (no) | Antivirale fosfinatforbindelser | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
WO2009024611A3 (en) | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
NO20083214L (no) | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer | |
EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
BR112014004560A2 (pt) | compostos e composições como inibidores de c-kit quinase | |
MA32393B1 (fr) | Composés et compositions servant d'inhibiteurs de kinases | |
EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
MY148634A (en) | Pyridazinone derivatives | |
NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
GEP20146197B (en) | New compounds | |
SMT201300109B (it) | Imidazopiridazincarbonitrili utili come inibitori di chinasi | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
BR112012002134B8 (pt) | compostos inibidores de apaf-1 | |
ATE520668T1 (de) | Sigmarezeptor-inhibitoren | |
DK2089369T3 (da) | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme | |
NO20084328L (no) | Nye forbindelser | |
UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |